Home/Stocks/Healthcare

ConvaTec Group PLC

CTEC.L·Healthcare·Market Cap £4.2b
Rank #26 of 100
Data from Excel Model · 100 Stocks Analysed
£1.96
-11.92% YTD
Target: £3.08(+56.9%)
52W: £1.99 - £3.11
Ad Space

Advertise with Strategyland

strategyland.uk

Score Analysis

ConvaTec Group PLC is ranked #26 out of 100 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

57/100
Average Score
Liquidity
Excellent20/100
Valuation
Weak86/100
Profitability
Excellent21/100
Solvency
Fair51/100
Asset Efficiency
Weak72/100
Mkt Trading
Weak66/100
Technical
Weak85/100

1. Valuation

Score: 86/100

Is CTEC undervalued compared to its peers and fair value metrics?

0/5
valuation criteria met
FY26e P/E Ratio
14.7xRank 53/100
FY27e P/E Ratio
12.8xRank 50/100
Price-to-Book
4.22xRank 68/100
Price-to-Tangible Book
N/ARank 101/100
EV/EBITDA
12.7xRank 67/100

Key Valuation Metrics

Current P/E
33.4x
Price-to-Earnings
FY26e P/E
14.7x
Forward estimate
FY27e P/E
12.8x
Forward estimate
P/B Ratio
4.22x
Price-to-Book
P/TBV
N/A
Price-to-Tangible Book
EV/EBITDA
12.7x
Enterprise Value
FY26e EV/EBITDA
9.8x
Forward estimate
FY27e EV/EBITDA
9.8x
Forward estimate

Analyst Consensus Target

Current Price
£1.96
Consensus Target
£3.08
Potential
+56.9%
Target
Bloomberg Median Target: £3.13

2. Profitability

Score: 21/100

How profitable is CTEC relative to its peers?

2/6
profitability criteria met
TTM Profit Margin
7.2%Rank 31/100
Current ROE
10.9%
Current ROA
N/A
FY26e EPS
0.23Rank 8/100
TTM EPS
0.21
Net Income Growth
N/A
Profit Margin
7.2%
ROE
10.9%
FY27e ROE
24.3%
ROA
N/A

Earnings Per Share

3. Financial Health

Score: 51/100

How strong is CTEC's balance sheet and financial position?

0/4
solvency criteria met
Debt-to-Equity
100.0%
Interest Coverage
N/A
Debt/EBITDA
Rank 47Rank 47/100
Altman Z-Score
3.37

Key Health Metrics

Quick Ratio
0.85
Below 1.0
Cash Ratio
1.53
Debt/Equity
100%
FCF Margin
0.1%

Altman Z-Score

3.37
Safe Zone
01.812.995+

4. Asset Efficiency

Score: 72/100

How efficiently does CTEC deploy its assets and intellectual capital?

1/2
asset efficiency criteria met
Intangible/Asset
Intangible assets as a proportion of total assets — lower indicates more tangible, capital-efficient operations
N/A
R&D/Sales
Research & development spend relative to revenue — balanced R&D investment signals sustainable growth
Rank 6/100

Overall Asset Efficiency Rank

Rank within sector peers#72/100
Best (1)Worst (100)

What This Measures

Intangible/Asset — a lower ratio suggests the company's value is backed by tangible assets rather than goodwill or intangibles, reducing balance sheet risk.

R&D/Sales — captures the proportion of revenue reinvested into research and development, indicating innovation intensity and future growth investment.

4. Dividend

CTEC pays a dividend yield of 2.02%.

Current Yield
2.02%
FY27e Yield
2.89%
FY26e DPS
0.040
FY27e DPS
N/A

Dividend Per Share Forecast

5. Technical Analysis

Score: 85/100

What do the technical indicators say about CTEC?

2/4
technical criteria met
CMP vs 52W High
-36.9%Rank 93/100
CMP vs 52W Low
-1.3%Rank 100/100
RSI 14 Day
55.1Rank 38/100
MA(50) > MA(200)
No (Bearish)Rank 40/100

RSI (14 Day)

55.1
Bullish
0 (Oversold)50100 (Overbought)

Moving Averages

MA 30-Day£2.19
MA 50-Day£2.22
MA 200-Day£2.33
SignalDeath Cross (Bearish)
MACD-3.71

Risk Metrics

Beta
N/A
3-Yr Std Dev
N/A
5-Yr Std Dev
N/A

6. Market Trading

Score: 66/100

How liquid and actively traded is CTEC?

1/4
market trading criteria met
5D Avg Volume
7.6M
3M Avg Volume
9.8MRank 19/100
Volume Trend
-22.4%
Beta
N/A
Shares Outstanding
1954852029.0m
Free Float
N/A
Enterprise Value
$7058031.8b

Trading Volume

7. Peer Comparison

How does CTEC compare to other Healthcare stocks?

Overall Rank Comparison

Factor Score Comparison

StockRankLiquidityValuationProfitabilitySolvencyMkt TradingTechnical
CTEC#26208621516685
SN.L#2183952395552
HLN.L#31728915183347
GSK.L#436487314937
AZN.L#72417693101010
Ad Space

Advertise with Strategyland

strategyland.uk

Note: The information provided is not intended as an offer or solicitation for the purchase or sale of any financial instruments but for investor relations purposes only. The aforementioned securities were offered to the public and currently trade on the secondary market at the exchange mentioned above. It is recommended that investors considering investing in any of these notes consult an approved MiFID Financial Advisor prior to investing.